DIAGNOS Announces the Extension of its Contract with Novo Nordisk for the Follow-up of Diabetic Patients Under Treatment with Drugs Included in its Therapeutic Portfolio
26 avr. 2022 09h00 HE
|
DIAGNOS Inc.
BROSSARD, Quebec, April 26, 2022 (GLOBE NEWSWIRE) -- Diagnos Inc. (“DIAGNOS”, the “Corporation” or “we”) (TSX Venture: ADK) (OTCQB: DGNOF), a leader in early detection of critical health issues...
DIAGNOS Announces Closing of Private Placement and New Marketing Director
28 mars 2022 16h15 HE
|
DIAGNOS Inc.
BROSSARD, Quebec, March 28, 2022 (GLOBE NEWSWIRE) -- DIAGNOS Inc. (“DIAGNOS” or the “Corporation”) (TSX Venture: ADK) (OTCQB: DGNOF), a leader in early detection of critical health issues through...
Le Réseau de santé CAN et DIAGNOS du Québec annoncent un partenariat pour un programme de dépistage de la rétinopathie diabétique qui change la vie
15 mars 2022 14h00 HE
|
DIAGNOS inc.
MONTRÉAL, 15 mars 2022 (GLOBE NEWSWIRE) -- Le Réseau national de santé accessible, coordonné (CAN) est heureux d’annoncer que DIAGNOS, entreprise de soins de la vue de premier plan, est la...
CAN Health Network and Quebec-Based DIAGNOS Announce Life-Changing Diabetic Retinopathy Screening Program Partnership
15 mars 2022 14h00 HE
|
DIAGNOS Inc.
MONTRÉAL, March 15, 2022 (GLOBE NEWSWIRE) -- The Coordinated Accessible National (CAN) Health Network is excited to announce that leading vision care company, DIAGNOS, is the first Quebec-based...
DIAGNOS Announces Closing of Private Placement
01 mars 2022 12h54 HE
|
DIAGNOS Inc.
BROSSARD, Quebec, March 01, 2022 (GLOBE NEWSWIRE) -- DIAGNOS Inc. (“DIAGNOS” or the “Corporation”) (TSX Venture: ADK) (OTCQB: DGNOF), a leader in early detection of critical health issues through...
DIAGNOS complète avec succès l’audit ISO / PAUMM
10 févr. 2022 10h14 HE
|
DIAGNOS inc.
BROSSARD, Québec, 10 févr. 2022 (GLOBE NEWSWIRE) -- Diagnos inc. (« DIAGNOS », la « Société » ou « nous ») (Bourse de croissance TSX : ADK) (OTCQB : DGNOF), un leader dans le dépistage...
DIAGNOS Successfully Completes ISO / MDSAP Audit
10 févr. 2022 10h14 HE
|
DIAGNOS Inc.
BROSSARD, Quebec, Feb. 10, 2022 (GLOBE NEWSWIRE) -- Diagnos Inc. (“DIAGNOS”, the “Corporation” or ”we”) (TSX Venture: ADK) (OTCQB: DGNOF) a leader in early detection of critical health issues...
DIAGNOS présente une mise à jour de l'entreprise pour 2021 et ses perspectives pour 2022
26 janv. 2022 09h00 HE
|
DIAGNOS inc.
BROSSARD, Québec, 26 janv. 2022 (GLOBE NEWSWIRE) -- Diagnos Inc. («DIAGNOS» ou la «Société») (Bourse de croissance TSX : ADK) (OTCQB : DGNOF), un leader dans la détection précoce des problèmes...
DIAGNOS Provides Corporate Update for 2021 and Outlook for 2022
26 janv. 2022 09h00 HE
|
DIAGNOS Inc.
BROSSARD, Quebec, Jan. 26, 2022 (GLOBE NEWSWIRE) -- Diagnos Inc. (“DIAGNOS” or the “Company”) (TSX Venture: ADK) (OTCQB: DGNOF), a leader in early detection of critical health issues based on...
DIAGNOS will be Attending in San Francisco during the J.P. Morgan Health Care Conference Week to be held from January 10th to 13th, 2022
15 déc. 2021 09h00 HE
|
DIAGNOS Inc.
BROSSARD, Quebec, Dec. 15, 2021 (GLOBE NEWSWIRE) -- Diagnos Inc. (“DIAGNOS” or the “Company”) (TSX Venture: ADK) (OTCQB: DGNOF), a leader in early detection of critical health issues, announces...